04 March 2022
binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced today the appointment of Jeff Grosklags, an accomplished industry leader and UnitedHealth Group’s Optum Rx Chief Financial Officer (CFO) to its Board of Directors. For the past 16 years, Grosklags has worked in a financial leadership capacity within Optum and UnitedHealth Group.
24 February 2022
Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent’s leading CAP/CLIA certified Next Generation Sequencing services with Epic’s best-in-class cell analysis platform as part of Epic’s novel DefineMBC liquid biopsy test.
23 February 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that due to the impact of the COVID-19 Omicron variant on hospital resources and an unexpected interruption of clinical supply material associated with IV ganaxolone, the RAISE, Phase 3, double-blind placebo-controlled trial for the treatment of status epilepticus, is now expected to be completed in the second half of 2023.
15 February 2022
binx health, a healthcare technology and diagnostics company that makes routine testing convenient, and the North Dakota Department of Health (NDDoH) are working together to combat the spread and support the treatment of sexually transmitted infections (STIs).
04 February 2022
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced preliminary results from an in vivo study on the M2 metabolite showing that no genotoxicity was found, as measured by formation of micronuclei in the bone marrow or comet morphology in the liver.
Epic Sciences and Biosplice Therapeutics Announce Partnership for Metastatic Cancer Trials
30 January 2022
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and Epic Sciences, Inc., a leading liquid biopsy diagnostic company, announce they are collaborating to incorporate multi-omic profiling in Biosplice’s clinical oncology programs, including Cirtuvivint (SM08502).
16 December 2021
Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. DefineMBC provides comprehensive MBC profiling when a tissue biopsy result is not available.
15 December 2021
Epic Sciences, Inc. (Epic)’s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate.
15 December 2021
binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced today that CB Insights ranked binx health among the most promising digital health startups in the world.
Epic Sciences Expands Leadership Team to Address Liquid Biopsy Demand
15 December 2021
Epic Sciences, Inc., developer of novel diagnostics to personalize and advance the treatment and management of cancer, today announced the appointment of Jason Christiansen as Chief Technology Officer, Mark Aguillard as Vice President/ General Manager of the Oncology Business Unit, and Amara Siva as Vice President of Laboratory Operations. These three new executives bring a combined 60 plus years of experience to the Epic Sciences team.
21 September 2023
September 21 is World Alzheimer's Day. NovaMedica supports this awareness raising campaign
21 September 2023
12 September 2023
AI-supported spectroscopy delivers superior pharmaceutical packaging QC
03 October 2023
Lymphoma maintenance therapy delivers promise in CTCL
03 October 2023
02 October 2023
The FAS implemented 864 new drug prices in 2022
02 October 2023